阿立派唑与利培酮治疗门诊首发精神分裂症的临床研究

A controlled study on aripiprazole and risperidone in the treatment of schizophrenic patients

目的比较阿立派唑与利培酮治疗首发精神分裂症的疗效和安全性。方法将70例符合CCMD-3和DSM-Ⅳ的精神分裂症诊断标准的首发病人随机分为两组,分别给予阿立派唑和利培酮治疗8周。在治疗前及治疗2、4、6、8周时采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果治疗8周后的疗效近似(P>0.05);阿立派唑组和利培酮组的显效率差异无显著性(P>0.05);阿立派唑组的副反应发生率低于利培酮组,且差异有显著性(P<0.01)。利培酮组锥体外系副反应和内分泌改变的发生均明显高于阿立派唑组(P<0.01)。两药的副作用均以轻、中度多见。结论阿立派唑和利培酮对首发精神分裂症的疗效相当,依从性好,副作用方面有一定的差异。

OBJECTIVE To research the therapeutic and side effects of aripiprazole in the treatment of first-run schizophrenic out-patients.METHODS 70 schizophrenic patients by CCMD-3 and DSM-Ⅳ were randomly allocated to two groups treated with aripiprazole and risperidone for 8 weeks.the positive and negative symptoms scale(PANSS) and the treatment emergent symptoms scale(TESS)were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment. RESULTS The total efficac...